

JAPAN TECHNOLOGY: SEMICONDUCTOR CAPITAL EQUIPMENT

Strong demand continues, but production capacity and pricing power to lead to varied profit margins; D/G Ulvac to Sell

With prices for SPE components also rising, equipment makers' pricing strategies to play an important part

Amid robust capex demand from semiconductor makers, tightness is emerging upstream in the supply chain. Moves to raise equipment prices are materializing, with TSMC mentioning rising production equipment prices at its recent results briefing. Additionally, according to our channel checks, prices for parts and materials used in production equipment are also beginning to rise. While SPE makers are expected to see strong demand for the time being, with continued requests from customers to bring forward shipments (particularly for front-end equipment), we believe trends in profit margins up ahead will vary significantly depending on each company's preparedness for the surge in demand, product competitiveness, and pricing strategies.

Shuhei Nakamura
+81(3)4587-9932 |
shuhei.nakamura@gs.com
Goldman Sachs Japan Co., Ltd.

Kaho Otake
+81(3)4587-7498 | kaho.otake@gs.com
Goldman Sachs Japan Co., Ltd.

Production capacity and product competitiveness at each company likely to determine strength/weakness of margins

As noted in our 2H CY26 investment strategy report, we focus on two key points for our individual stock recommendations: (1) whether a company can achieve sales growth above the sector average through technological change, proprietary technology, or market share gains, and (2) whether top-line strength translates into a substantial improvement in profit margins (Exhibit 1, Exhibit 2). As to profit margins in particular, in addition to product/customer mix, we believe key factors will be production capacity, lead time status, and the strength or weakness of pricing power to cope with cost inflation. We summarize current conditions at individual companies and our views on their pricing strategies in Exhibit 3.

Downgrade Ulvac given potential for profit margin expansion to be limited

For four equipment makers on which we maintain our Buy ratings—**Lasertec (on CL)**, **Ebara**, **Disco**, and **Tokyo Electron**—we see a high likelihood that all of them will achieve sales growth exceeding the sector average and profit margin expansion over FY26-FY27. For **Ulvac**, in contrast, while orders continue to grow on the back of tailwinds in the market environment, we note that it is approaching full production capacity in its semiconductor equipment products, and appears to lack upward

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

elasticity to cope with further demand expansion. We also see a strong possibility that improvement in its profit margins will be limited due to prolonged lead times and rising costs for component procurement. We lower our rating to Sell from Neutral based on a relative comparison within our coverage.

Ulvac: Phase of order growth to continue, but hurdle for margin expansion has risen; downgrade to Sell on relative basis

Lower GSe/TP, see limited room for price hikes against cost increases, in addition to prolonged lead times

We downgrade Ulvac from Neutral to Sell. We assume downside of c.18% to our new 12-month target price of ¥8,200 (vs. coverage average of c.+20%). While orders in Ulvac's semiconductor products are on an expansion trend amid capex increases by major semiconductor makers, our new earnings estimates assume the pace of margin improvement at the company may be restrained. Key reasons are as follows. 1) Production capacity at its main bases is already nearing its limit, leaving little room for further output increases, and lead times are trending longer, meaning the timing of sales recognition could be later than previously assumed. 2) While we believe rising component costs can be absorbed to some extent by reflecting them in estimates at the time of order receipt, we think it will be difficult for the company to implement aggressive price hikes in equipment groups other than power semiconductors, where it boasts a high market share, due to its market share positioning. Reflecting these factors, we lower our FY6/27-FY6/29 operating profit estimates by 18%/15%/12%. Our new estimate for FY6/28 is over 20% below the market (Bloomberg) consensus.

Order growth strong, but margin improvement on back of production reforms may be slow

In FY6/23, Ulvac revised down its guidance partly due to the impact of longer delivery times for components, and we view this as an example of its mixed track record during phases of order growth and prolonged lead times. The company has recently been trying to improve profit margins by securing components in advance via equipment modularization and by promoting planned production ahead of order receipt. While some progress can be seen, the equipment modularization ratio was only at c.30% in FY6/26, and lead times are currently trending longer. Accordingly, we think profit margin improvement on the back of production reforms may not materialize to the extent management expects. We forecast an operating margin of 11.8% for FY6/28, and while we expect some fixed cost reduction effects from structural reforms, we do not see the 15% target in the company's medium-term plan as a low hurdle to clear (Exhibit 4).

New TP at ¥8,200; referencing correlation between margins and multiples

Reflecting our estimate revisions, we lower our 12-month target price from ¥10,300 to ¥8,200. We derive our TP by applying the global SPE sector average EV/EBITDA of 18X to our FY6/28 EBITDA estimate, then applying a discount given Ulvac's relatively low margins (our TP implies FY6/28E P/E of 17X, P/B of 1.5X, and EV/EBITDA of 8X). As our estimate revisions result in lower profit margin assumptions, we widen our applied discount from 50% to 55%, referencing the relationship between EBITDA margins and EV/EBITDA multiples for companies in our SPE coverage (Exhibit 7). Ulvac's P/E range over the past five years or so has been from just under 10X to slightly over 20X (Exhibit 5), and the stock does not look undervalued given that the current share price implies a P/E of 19X based on our new FY6/28 estimates.

Pricing strategy key to profit margin expansion

Setsuo Iwashita, who served as company president from 2017, has promoted a series of corporate and organizational reforms aimed at improving profitability. Some results have been achieved, such as the gross margin reaching a record high of 31.8% in FY6/25. On the other hand, Ulvac has yet to reach the 35% gross margin level targeted in past medium-term plans, and a back-and-forth situation continues. In addition to fixed/variable cost reductions, we think product price hikes will be important to any upcoming profit margin expansion scenarios, and we will be paying close attention to the leadership of Junya Kiyota, who newly assumed the position of President & Executive Officer as of July 1, 2026.

Key risks include margin improvement from early materialization of structural reform effects or implementation of price hikes, and power semiconductor market recovery

Key upside risks to our view are as follows.

(1) Profitability improvement through early materialization of structural reform effects or price hikes

If, under the new management team, profitability improvements from ongoing structural reforms materialize ahead of the company's assumption of FY6/28, or if it implements product price hikes, an area where management has historically been passive, this could pose upside risk to our earnings estimates.

(2) A further expansion of orders accompanied by upward capacity elasticity

While we expect the favorable order environment to continue, mainly in the semiconductor field, we believe there is little upward sales elasticity as the company's production capacity nears its upper limit. However, if capacity bottlenecks are resolved through productivity improvements or the utilization of other bases, sales and profits could exceed our assumptions.

(3) Recovery in power semiconductor investment in the Chinese market

Against the backdrop of a weak EV market, power semiconductor capex is currently low, and Ulvac's power semiconductor sales are down to less than one-third of their recent peak. However, if capex appetite in China's SiC market increases, Ulvac, which commands a high market share in ion implanters, could see an expansion in orders. With margins on these products relatively high, the pace of profitability improvement could accelerate more than we expect.

(4) Market favoring stocks with low valuations

We believe there is correlation between profitability and multiples within our coverage, and based on our future margin forecasts, we do not expect Ulvac's valuation multiple to expand significantly. However, the outcome could differ from our scenario if changes in stock market risk tolerance or a sharp rise in interest rates result in a market environment that favors stocks with relatively low multiples.


Ulvac: Summary

6728.T	12m Price Target: ¥8200	Price: ¥9610	Downside: 14.7%			
Sell	GS Forecast					
		6/25	6/26E	6/27E	6/28E	
	Market cap: ¥473.2bn / \$2.9bn	Revenue (¥ bn)	251.2	266.7	271.1	287.6
	Enterprise value: ¥431.4bn / \$2.6bn	Op. profit (¥ bn) New	26.5	20.9	26.6	33.9
	3m ADTV :¥5.4bn/ \$33.8mn	Op. profit (¥ bn) Old	26.5	20.9	32.3	39.8
	Japan	Op. profit CoE (¥ bn)	--	19.0	--	--
	Japan Semiconductor, SPE & Precision	EPS (¥) New	338.9	398.7	390.5	496.3
		EPS (¥) Old	338.9	406.8	488.2	600.0
	M&A Rank: 3	P/E (X)	19.2	24.1	24.6	19.4
	Leases incl. in net debt & EV?: No	P/B (X)	1.4	2.0	1.9	1.8
	CROCI (%)	9.8	9.5	9.3	10.5	
		3/26	6/26E	9/26E	12/26E	
	EPS (¥)	59.1	213.8	103.5	109.6	

Source: Company data, Goldman Sachs Research estimates, FactSet. Price as of 24 Jul 2026 close.

Exhibit 1: We expect Ulvac's top-line growth to remain relatively low even after adjusting for business divestitures


Sales growth rates for SPE coverage companies (FY25-FY27)



Source: Company data, Goldman Sachs Global Investment Research

Exhibit 2: Expecting change in profitability to be relatively gradual


Change in OPM for SPE coverage companies (FY25-FY27)



Source: Goldman Sachs Global Investment Research, Company data

Exhibit 3: Comparison of production capacity, lead times, and pricing power among SPE coverage companies


Exhibit 6: Ulvac: P/B



Source: Bloomberg

Exhibit 7: We see a correlation between margins and multiples

Correlation between EBITDA margin and EV/EBITDA for SPE coverage (based on our FY27 estimates and current share prices)



Source: LSEG Data & Analytics, Goldman Sachs Global Investment Research

Exhibit 8: Ulvac: Earnings summary

Ulvac (6728.T) (JPY mn)						Mid-term												
Consolidated income statement						CoE	CoE	CoE	GSE	GSE	GSE	GSE	GSE	GSE	GSE	GSE	CoE	
	6/2025	6/2026	6/2027	6/2028	6/2029	6/2026	6/2028	6/2031	6/2026 1Q	6/2026 2Q	6/2026 3Q	6/2026 4Q	6/2027 1Q	6/2027 2Q	6/2027 3Q	6/2027 4Q	6/2026 4Q	
Sales	251,184	266,700	271,100	287,600	307,200	260,000	260,000	360,000	52,729	71,164	67,738	75,069	66,800	75,100	68,500	60,700	68,369	
Operating profits	26,523	20,900	26,600	33,900	39,000	19,000	19,000	39,000	2,284	6,172	6,263	6,181	6,900	7,300	8,500	3,900	4,281	
Recurring profits	28,605	22,000	28,000	35,400	40,700	19,000	19,000	39,000	2,480	6,674	5,360	7,466	7,300	7,700	8,900	4,100	4,466	
Net income	16,687	19,600	19,200	24,400	28,100	18,500			1,562	4,538	2,911	10,488	5,100	5,400	6,200	2,500	9,388	
EBITDA	37,328	32,600	39,300	47,500	53,400	30,700												
Margins																		
Gross profits	31.8%	29.9%	31.4%	33.0%	33.8%	29.6%			29.7%	29.1%	32.0%	28.9%	31.0%	30.5%	33.4%	30.5%	27.7%	
EBITDA	14.9%	12.2%	14.5%	16.5%	17.4%				4.3%	8.7%	9.2%	8.2%	10.3%	9.7%	12.4%	6.4%	6.3%	
Operating profits	10.6%	7.8%	9.8%	11.8%	12.7%	7.3%	15.0%	22.0%	4.7%	9.4%	7.9%	9.9%	10.9%	10.3%	13.0%	6.8%	6.5%	
Recurring profits	11.4%	8.2%	10.3%	12.3%	13.2%	7.3%			3.2%	6.4%	4.3%	14.0%	7.6%	7.2%	9.1%	4.1%	13.7%	
Net income	6.6%	7.3%	7.1%	8.5%	9.1%	7.1%												
R&D	13,991	14,000	14,500	15,000	16,000	14,000												
D&A	10,805	11,700	12,700	13,600	14,400	11,700												
Capex	15,715	17,500	20,000	20,000	20,000	17,500												
EPS (JPY)	338.7	398.7	390.5	496.3	571.6	376.0												
DPS (JPY)	164.0	159.0	137.0	174.0	200.0	152.0												
BPS (JPY)	4,538.0	4,785.0	5,038.6	5,360.9	5,732.4													
Order by segment segment																		
Vacuum equipment business	173,430	260,500	240,200	257,800	276,300	253,000			45,854	62,501	63,289	68,856	54,500	63,500	60,000	62,200	61,356	
Display & Energy	46,500	71,200	40,000	42,000	47,000	70,000			13,000	18,300	11,900	28,000	10,000	12,000	12,000	6,000	26,800	
Semiconductor & Electronics	70,400	115,300	124,500	138,300	149,900	109,000			18,000	28,700	41,500	27,100	29,000	29,500	32,000	34,000	20,800	
Component	39,900	34,000	35,700	37,500	39,400	34,000			7,800	8,800	10,100	7,300	8,500	9,000	9,000	9,200	7,300	
Industrial equipment	16,800	40,000	40,000	40,000	40,000	40,000			7,000	6,700	19,800	6,500	7,000	13,000	7,000	13,000	6,500	
Vacuum application business	52,137	56,000	34,400	36,900	38,700	57,000			14,554	14,196	15,791	11,459	8,500	8,500	8,500	8,900	12,459	
Materials	26,200	27,500	14,500	16,000	16,800	28,000			7,800	8,000	8,200	3,500	3,500	3,500	3,500	4,000	4,000	
Others	25,900	28,500	19,900	20,900	21,900	29,000			6,800	6,200	7,600	7,900	5,000	5,000	5,000	4,900	8,400	
Total	225,567	316,500	274,600	294,700	315,000	310,000			60,408	76,700	99,077	80,315	63,000	72,000	68,500	71,100	73,815	
Revenue by business segment																		
Vacuum equipment business	199,050	209,600	236,700	250,700	268,500	205,000			40,159	55,711	54,135	59,595	58,300	66,600	60,000	51,800	54,995	
Display & Energy	53,100	59,000	55,600	41,000	44,500	59,000			11,089	19,660	14,720	13,531	17,800	17,100	15,500	5,200	13,531	
Semiconductor & Electronics	89,300	94,300	113,400	130,200	142,600	89,000			16,153	21,270	25,640	31,237	26,500	28,000	28,500	30,400	25,937	
Component	43,100	34,000	35,700	37,500	39,400	35,000			8,379	8,791	8,784	8,046	7,000	13,000	7,000	8,700	9,046	
Industrial equipment	13,500	22,300	32,000	42,000	42,000	22,000			4,538	5,991	4,990	6,781	7,000	8,500	9,000	7,500	6,481	
Vacuum application business	52,134	57,100	34,400	36,900	38,700	55,000			12,570	15,453	13,603	15,474	8,500	8,500	8,500	8,900	13,374	
Materials	26,800	28,900	14,500	16,000	16,800	26,000			6,290	7,249	6,321	7,040	3,500	3,500	3,500	4,000	6,140	
Others	25,500	30,200	19,900	20,900	21,900	29,000			6,279	8,205	7,283	8,433	5,000	5,000	5,000	4,900	7,233	
Total	251,184	266,700	271,100	287,600	307,200	260,000	260,000	360,000	52,729	71,164	67,738	75,069	66,800	75,100	68,500	60,700	68,369	
OP by business segment									1,575	5,258	5,936	5,431	6,400	6,700	7,800	3,200		
Vacuum equipment business	21,877	18,200	24,100	30,800	35,600				710	840	313	837	500	600	700	700		
Vacuum application business	4,533	2,700	2,500	3,100	3,400				(1)	0	73	15	(87)	0	0	0		
Adjustments	113	0	0	0	0				2,284	6,172	6,263	6,181	6,900	7,300	8,500	3,900	4,281	
Total	26,523	20,900	26,600	33,900	39,000	19,000	48,000	48,000										
OPM by business segment																		
Vacuum equipment business	11.0%	8.7%	10.2%	12.3%	13.3%				3.9%	9.4%	11.0%	9.1%	11.0%	10.1%	13.0%	6.2%		
Vacuum application business	8.7%	4.7%	7.3%	8.4%	8.8%				5.6%	5.4%	2.3%	5.4%	5.9%	7.1%	8.2%	7.9%		
Total	10.6%	7.8%	9.8%	11.8%	12.7%	7.3%	18.5%	13.3%	4.3%	8.7%	9.2%	8.2%	10.3%	9.7%	12.4%	6.4%	6.3%	

Source: Company data, Goldman Sachs Global Investment Research



Exhibit 9: Summary financial statements

Profit model (¥mn)	6/26E	6/27E	6/28E	6/29E	Balance sheet (¥mn)	6/26E	6/27E	6/28E	6/29E
Revenue	266,700	271,100	287,600	307,200	Cash & equivalents	96,046	97,260	97,362	98,875
Cost of goods sold	-187,000	-186,100	-192,700	-203,900	Accounts receivable	89,972	91,457	97,023	103,635
Gross profit	79,700	85,000	94,900	103,300	Inventory	77,626	77,253	79,992	84,642
SG&A and other	-44,800	-43,900	-46,000	-48,300	Other current assets	15,270	15,270	15,270	15,270
Operating profit	20,900	26,600	33,900	39,000	Total current assets	278,914	281,240	289,648	302,421
Net interest income/(expense)	0	200	300	400	Net PP&E	82,721	90,021	96,421	102,021
Equity in earnings of affiliates	700	700	700	700	Net intangibles	5,685	5,685	5,685	5,685
Net other nonoperating inc/(exp)					Total investments	8,696	9,396	10,096	10,796
Recurring profit	22,000	28,000	35,400	40,700	Other long-term assets	14,384	14,384	14,384	14,384
Extraordinary income					Total assets	390,400	400,726	416,234	435,307
Extraordinary expense					Accounts payable	42,430	42,226	43,724	46,265
Pretax profit	28,000	28,000	35,400	40,700	Short-term debt	12,853	12,853	12,853	12,853
Income tax	-7,400	-7,600	-9,700	-11,200	Other current liabilities	51,061	51,061	51,061	51,061
Minority interest	-1,000	-1,200	-1,300	-1,400	Total current liabilities	106,344	106,140	107,638	110,179
Net income	19,600	19,200	24,400	28,100	Long-term debt	32,743	29,608	26,473	23,338
					Other long-term liabilities	7,450	7,450	7,450	7,450
Capital expenditures (excl. leases)					Total long-term liabilities	40,193	37,058	33,923	30,788
Capital expenditures (incl. leases)	-17,500	-20,000	-20,000	-20,000	Total liabilities	146,537	143,198	141,561	140,967
Depreciation & amortization	-11,700	-12,700	-13,600	-14,400	Minority interest	8,615	9,815	11,115	12,515
EPS (basic) (¥)	398.7	390.5	496.3	571.6	Total common equity	235,248	247,713	263,558	281,825
EPS (fully diluted) (¥)	398.7	390.5	496.3	571.6	Total liabilities & equity	390,400	400,726	416,234	435,307
BVPS (¥)	4,785.0	5,038.6	5,360.9	5,732.4	Net debt	(50,450)	(54,799)	(58,036)	(62,684)
DPS (¥)	159.0	137.0	174.0	200.0					
Dividend payout ratio (%)	39.9	35.1	35.1	35.0	Ratios	6/26E	6/27E	6/28E	6/29E
Year-on-year change (%)	6/26E	6/27E	6/28E	6/29E	CROCI (%)	9.5	9.3	10.5	11.1
Revenue	6.2	1.6	6.1	6.8	ROE (%)	8.3	7.7	9.2	9.9
Operating profit	-21.2	27.3	27.4	15.0	ROA (%)	5.1	4.9	6.0	6.6
Recurring profit	-23.1	27.3	26.4	15.0	Net debt/equity (%)	-20.7	-21.3	-21.1	-21.3
Net income	17.4	-2.0	27.1	15.2	Interest coverage ratio (X)	34.8	53.2	67.8	78.0
EPS (basic)	17.7	-2.0	27.1	15.2					
EPS (fully diluted)	17.7	-2.0	27.1	15.2	Valuation	6/26E	6/27E	6/28E	6/29E
Margins (%)	6/26E	6/27E	6/28E	6/29E	P/E (X)	25.0	25.5	20.1	17.4
Operating profit	7.8	9.8	11.8	12.7	EV/EBITDA (X)	13.8	11.3	9.3	8.2
EBITDA	12.2	14.5	16.5	17.4	EV/GCI (X)	1.3	1.3	1.2	1.1
Recurring profit	8.2	10.3	12.3	13.2	P/B (X)	2.1	2.0	1.9	1.7
Net income	7.3	7.1	8.5	9.1	Dividend yield (%)	1.6	1.4	1.7	2.0
Cash flow statement (¥mn)	6/26E	6/27E	6/28E	6/29E	FCF yield (%)	1.2	2.2	2.4	2.9
Net income	19,600	19,200	24,400	28,100					
D&A add-back	11,700	12,700	13,600	14,400					
Minority interest add-back	1,000	1,200	1,300	1,400					
Net (inc)/dec in working capital	-8,185	-1,315	-6,809	-8,720					
Other operating cash flow	-700	-700	-700	-700					
Cash flow from operations	23,415	31,085	31,791	34,480					
Capital expenditures (incl. leases)	-17,500	-20,000	-20,000	-20,000					
Purchases of long-term securities									
Sales of long-term securities									
Other investing cash flow	0	0	0	0					
Cash flow from investments	-17,500	-20,000	-20,000	-20,000					
Dividends paid (common & preferred)	-7,817	-6,735	-8,554	-9,833					
Incr./(decr.) in debt	-1,003	-3,135	-3,135	-3,135					
Common stock issuance									
Other financing cash flow	0	0	0	0					
Cash flow from financing	-8,820	-9,870	-11,689	-12,968					
Total cash flow	-2,905	1,215	102	1,512					

Note: Last actual year may include reported and estimated data.

Source: Company data, Goldman Sachs Global Investment Research

Exhibit 10: Price target risks and methodologies

Company Name (rating)	Ticker	12-m TP (¥)	Methodology	Risks
DISCO (Buy)	6146.T	100,000	Based on the global SPE sector average EV/EBITDA multiple of 18X and our FY3/28E estimates. We then apply a sector-relative premium of 50%.	(-) slowdown or share loss in AI-related demand (-) slowdown in China demand or tightening of export controls (-) rapid yen appreciation against the USD
Ebara (Buy)	6361.T	7,900	Based on the correlation between P/B and our FY12/27E ROE estimates.	(-) Semiconductor capex enters a downcycle (-) Increasing competitiveness of Chinese CMP system makers (-) Slow adoption of new technology in semiconductor devices (-) Decline in crude oil/LNG prices, oil refining/petrochemical margins
Kokusai Electric (Neutral)	6525.T	9,500	Based on the global SPE sector average EV/EBITDA multiple of 18X and our FY3/28E estimates.	(+/-) Changes in investment at key customers (+/-) Additional changes in export controls (+/-) Changes in the competitive landscape due to strategic changes at competitors
Advantest (Neutral)	6857.T	35,000	Based on the global SPE sector average EV/EBITDA multiple of 18X and our FY3/28E estimates. We then apply a sector-relative premium of 40%.	(+/-) fluctuations in customer capex appetite (+/-) fluctuations in market share (+/-) trends in tester demand for China (+/-) FX fluctuations for JPY/USD
Lasertec (Buy)*	6920.T	70,000	Based on the global SPE sector average EV/EBITDA multiple of 18X and the average of our FY6/28E estimates. We then apply a sector-relative premium of 50%.	(-) Decline in market share due to new entrants (-) Lack of progress in ACTIS adoption by wafer fabs (-) Weaker customer investment appetite for leading-edge process nodes (-) Rapid appreciation of the yen against the US dollar
JEOL (Neutral)	6951.T	8,300	Based on the global SPE sector average EV/EBITDA multiple of 18X and our FY3/28E estimates. We then apply a sector-relative discount of 50%.	(+/-) substantial changes in investment appetite at major mask shops (+/-) changes in market share for multi-beam mask writers (+/-) sharp fluctuations in the USD/JPY exchange rate.
Tokyo Seimitsu (Sell)	7729.T	15,000	Based on the global SPE sector average EV/EBITDA multiple of 18X and our FY3/28E estimates, to which we apply a sector-relative discount of 40%.	(+) greater-than-expected semiconductor orders (especially related to generative AI) (+) substantial beat in the metrology instruments segment (+) greater shareholder returns than we expect
SCREEN HD (Sell)	7735.T	12,500	Based on the global SPE sector average EV/EBITDA multiple of 18X and our FY3/28E estimates, to which we apply a sector-relative discount of 40%.	(+) higher profit margins in the SPE business (+) market share gains due to company-specific factors (+) enhancement of shareholder returns (+) a market shift in favor of value stocks
Tokyo Electron (Buy)	8035.T	83,000	Based on the global SPE sector average EV/EBITDA multiple of 18X and our FY3/28E estimates. We then apply a sector-relative premium of 30%.	(-) prolonged inventory adjustment phase in the semiconductor industry (-) further strengthening of export restrictions (-) depressed valuation multiple amid upward pressure on interest rates and other factors

*APAC Conviction List

Source: Goldman Sachs Global Investment Research

Investment Thesis - Ulvac

While orders in Ulvac's semiconductor products are on an expansion trend amid capex increases by major semiconductor makers, we think there is a high possibility that the pace of margin improvement will be restrained. Key reasons are as follows. 1) Production capacity at its main bases is already nearing its limit, leaving little room for further output increases, and lead times are trending longer, meaning the timing of sales recognition could be later than previously assumed. 2) While we believe rising component costs can be absorbed to some extent by reflecting them in estimates at the time of order receipt, we think it will be difficult for the company to implement aggressive price hikes in equipment groups other than power semiconductors, where it boasts a high market share, due to its market share positioning. The company has recently been trying to improve profit margins by securing components in advance via equipment modularization and by promoting planned production ahead of order receipt. While some progress can be seen, the equipment modularization ratio was only at c.30% in FY6/26, and lead times are currently trending longer. Accordingly, we think profit margin improvement on the back of production reforms may not materialize to the extent management expects. Ulvac's P/E range over the past five years or so has been from just under 10X to slightly over 20X, and the stock does not look undervalued given that the current share price implies a P/E of 19X based on our new FY6/28 estimates. We are Sell rated.

Price Target Risks and Methodology - Ulvac

Valuation methodology: We are Sell rated on Ulvac, with a 12-month target price of ¥8,200 (implies FY6/28E P/E of 17X and P/B of 1.5X). Our TP is based on our FY6/28E earnings estimates and an EV/EBITDA multiple of 18X, the global SPE sector average, to which we apply a sector-relative discount of 55% to reflect recent valuation trends and uncertainty around Ulvac's China business.

Key risks: Profitability improvement through early materialization of structural reform

effects or price hikes, a further expansion of orders accompanied by upward capacity elasticity, recovery in power semiconductor investment in the Chinese market, and the market favoring stocks with low valuations

Disclosure Appendix

Reg AC

We, Shuhei Nakamura and Kaho Otake, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

Contributing Authors: Shuhei Nakamura Goldman Sachs Japan Co., Ltd., Kaho Otake Goldman Sachs Japan Co., Ltd..

Unless otherwise stated, the individuals listed in the Contributing Authors disclosure of this report are analysts in Goldman Sachs' Global Investment Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

Rating and pricing information

Advantest (Neutral, ¥28,945), JEOL (Neutral, ¥8,194), Kokusai Electric (Neutral, ¥8,563), SCREEN Holdings (Sell, ¥15,850) and Tokyo Seimitsu (Sell, ¥17,520)

The rating(s) for DISCO, Ebara, Lasertec, Tokyo Electron and Ulvac is/are relative to the other companies in its/their coverage universe:

Advantest, DISCO, Ebara, HOYA, JEOL, Kioxia Holdings, Kokusai Electric, Lasertec, SCREEN Holdings, Tokyo Electron, Tokyo Seimitsu, Ulvac

Company-specific regulatory disclosures

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by Goldman Sachs Global Investment Research and referred to in this research.

Goldman Sachs beneficially owned 1% or more of common equity (excluding positions managed by affiliates and business units not required to be aggregated under US securities law) as of the month end preceding this report: Ebara (¥5,681), Lasertec (¥43,170) and Ulvac (¥9,622)

Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: DISCO (¥60,890), Ebara (¥5,681), Lasertec (¥43,170), Tokyo Electron (¥62,660) and Ulvac (¥9,622)

Goldman Sachs has received compensation for non-investment banking services during the past 12 months: Tokyo Electron (¥62,660)

Goldman Sachs had an investment banking services client relationship during the past 12 months with: DISCO (¥60,890), Ebara (¥5,681), Lasertec (¥43,170), Tokyo Electron (¥62,660) and Ulvac (¥9,622)

Goldman Sachs had a non-investment banking securities-related services client relationship during the past 12 months with: Tokyo Electron (¥62,660)

Goldman Sachs had a non-securities services client relationship during the past 12 months with: DISCO (¥60,890), Ebara (¥5,681) and Tokyo Electron (¥62,660)


Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe


	Rating Distribution			Investment Banking Relationships		
	Buy	Hold	Sell	Buy	Hold	Sell
Global	50%	34%	16%	65%	59%	43%

As of July 1, 2026, Goldman Sachs Global Investment Research had investment ratings on 3,104 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See ‘Ratings, Coverage universe and related definitions’ below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.


Price target and rating history chart(s)




The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.




The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.

Target price history table(s)

DISCO (6146.T)

Date of report	Target price (¥)	Closing price (¥)
06-Jul-26	100,000	78,000
30-Jun-26	95,000	81,260
31-May-26	87,000	65,090
22-Apr-26	86,000	74,830
09-Mar-26	83,000	66,500
21-Jan-26	68,000	58,570
08-Jan-26	64,000	55,590
06-Jan-26	62,000	54,200
29-Oct-25	61,000	56,390
08-Oct-25	60,000	52,140
06-Oct-25	56,000	54,000
09-Jul-25	51,000	41,290
30-Jun-25	47,000	42,630
13-Apr-25	43,000	27,470
04-Apr-25	44,000	27,635
24-Mar-25	51,000	33,060
21-Nov-24	59,000	42,380
01-Nov-24	57,000	42,810
04-Oct-24	54,000	39,710
02-Oct-24	56,000	37,410
02-Sep-24	63,000	41,350
22-Aug-24	66,000	43,560
04-Jul-24	71,000	64,580
27-May-24	65,000	61,790
04-Apr-24	60,000	56,750
21-Mar-24	56,000	52,960
13-Mar-24	53,000	50,000
31-Jan-24	43,000	40,380
24-Jan-24	42,000	40,730
04-Jan-24	39,000	33,630
21-Nov-23	34,000	32,030
26-Oct-23	32,000	26,960
05-Oct-23	31,000	27,940
15-Aug-23	30,000	25,865

Tokyo Electron (8035.T)

Date of report	Target price (¥)	Closing price (¥)
30-Jun-26	83,000	77,150
31-May-26	62,000	52,420
04-May-26	57,000	47,450
30-Apr-26	55,000	44,390
09-Mar-26	52,000	38,920
21-Feb-26	50,000	43,960
06-Feb-26	44,000	41,030
06-Jan-26	43,000	37,350
15-Dec-25	38,000	31,140
31-Oct-25	36,000	34,180
08-Oct-25	32,500	29,255
31-Jul-25	30,000	27,330
30-Jun-25	33,000	27,680
07-Apr-25	30,000	17,060
24-Mar-25	32,500	22,190
10-Jan-25	35,000	27,025
02-Oct-24	38,500	25,080
02-May-24	43,000	35,010
21-Mar-24	41,000	39,340
13-Mar-24	40,000	37,390
09-Feb-24	33,000	29,755
04-Jan-24	30,000	24,005
25-Nov-23	27,000	24,005

Ebara (6361.T)

Date of report	Target price (¥)	Closing price (¥)
22-Jul-26	7,900	5,593
30-Jun-26	7,800	6,256
31-May-26	7,100	5,683
04-May-26	7,000	5,242
15-Apr-26	6,800	5,004
21-Feb-26	6,600	5,638
13-Feb-26	5,900	5,303
06-Jan-26	5,200	4,050
10-Dec-25	5,000	3,942

Ulvac (6728.T)

Date of report	Target price (¥)	Closing price (¥)
30-Jun-26	10,300	10,345
31-May-26	9,400	9,504
12-May-26	12,000	11,320
09-Mar-26	11,500	9,054
21-Feb-26	10,900	10,410
10-Feb-26	9,500	8,817
06-Jan-26	8,400	7,481
08-Oct-25	7,700	6,589
13-Aug-25	6,700	5,619
30-Jun-25	6,600	5,306
13-May-25	6,500	5,300
07-Apr-25	7,100	3,991
24-Mar-25	8,100	5,499
12-Feb-25	8,700	6,223
10-Jan-25	9,300	6,257
21-Nov-24	9,700	6,260
11-Nov-24	9,900	7,357
02-Oct-24	11,000	7,503
27-May-24	12,000	11,235
14-May-24	11,700	9,700

Ebara (6361.T)

Date of report	Target price (¥)	Closing price (¥)
----------------	------------------	-------------------

Ulvac (6728.T)

Date of report	Target price (¥)	Closing price (¥)
----------------	------------------	-------------------

02-May-24	11,300	9,700
21-Mar-24	10,500	9,862
13-Mar-24	10,000	9,407
13-Feb-24	9,000	7,888
04-Jan-24	8,000	6,408
25-Nov-23	7,200	6,539
19-Sep-23	6,800	5,474

Lasertec (6920.T)

Date of report	Target price (¥)	Closing price (¥)
----------------	------------------	-------------------

22-Jul-26	70,000	42,990
30-Jun-26	67,000	49,700
04-May-26	55,000	42,930
30-Apr-26	53,000	42,690
09-Mar-26	50,000	30,360
21-Feb-26	28,000	30,640
06-Jan-26	27,000	32,760
15-Dec-25	24,000	30,300
31-Oct-25	22,500	28,410
08-Oct-25	20,000	20,030
07-Aug-25	19,000	14,295
30-Jun-25	19,500	19,410
12-May-25	17,500	14,775
07-Apr-25	17,000	10,585
24-Mar-25	18,000	14,040
31-Jan-25	20,000	15,470
10-Jan-25	21,500	15,655
21-Nov-24	24,500	17,280
31-Oct-24	28,500	23,475
02-Oct-24	30,000	22,785
07-Aug-24	34,000	22,170
10-May-24	33,000	40,940
30-Apr-24	30,000	34,600
21-Mar-24	26,500	43,060
13-Mar-24	25,500	38,270
04-Jan-24	22,500	35,220
25-Nov-23	21,000	30,970
05-Oct-23	19,500	22,890

Price targets shown in table(s) are unadjusted for corporate actions.

Regulatory disclosures**Disclosures required by United States laws and regulations**

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with a subject company, public appearances and trading in securities covered by the analysts.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in

part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at <https://www.gs.com/worldwide/brazil/area/gir/index.html>. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 10th Floor, Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai-400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details, a copy of the annual compliance audit report and other relevant information and disclosures can be found at this link: <https://www.goldmansachs.com/worldwide/india/research-analyst>. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <https://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, and Investment Management Association of Japan. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at <https://www.gs.com/research/hedge.html>.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. **Early-Stage Biotech (ES).** An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company has neither a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research within the European Economic Area.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<https://www.sipc.org>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <https://www.theocc.com/about/publications/character-risks.jsp> and https://www.goldmansachs.com/disclosures/cftc_fcm_disclosures. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <https://research.gs.com>.

Disclosure information is also available at <https://www.gs.com/research/hedge.html> or from Research Compliance, 200 West Street, New York, NY 10282.

© 2026 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.